Invex Therapeutics (ASX:IXC) Cash Flow from Operations : A$-5.27 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2023, Invex Therapeutics's Cash Receipts from Operating Activities was A$0.00 Mil. Its Cash Payments was A$-2.69 Mil. Its Dividends Paid was A$0.00 Mil. Its Dividends Received was A$0.00 Mil. Its Interest Paid was A$0.00 Mil. Its Interest Received was A$0.38 Mil. Its Taxes Refund Paid was A$0.00 Mil. And its Cash Flow from Others was A$0.00 Mil. In all, Invex Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2023 was A$-2.32 Mil.

Invex Therapeutics Cash Flow from Operations Historical Data

The historical data trend for Invex Therapeutics's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Cash Flow from Operations Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Cash Flow from Operations

-1.60

-1.68

-3.38

-6.87

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash Flow from Operations	Get a 7-Day Free Trial				-1.35	-2.03	-3.92	-2.95	-2.32

Invex Therapeutics Cash Flow from Operations Calculation

Invex Therapeutics's Cash Flow from Operations for the fiscal year that ended in Jun. 2023 is calculated as:

	Cash Flow from Operations		(A: Jun. 2023 )
=	Cash Receipts from Operating Activities	+	Cash Payments	+	Dividends Paid	+	Dividends Received
=	0.459	+	-8.125	+	0	+	0
+	Interest Paid	+	Interest Received	+	Taxes Refund Paid	+	Cash Flow from Others
+	0	+	0.797	+	0	+	8.8817841970013E-16
=	-6.87

Invex Therapeutics's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:

	Cash Flow from Operations		(Q: Dec. 2023 )
=	Cash Receipts from Operating Activities	+	Cash Payments	+	Dividends Paid	+	Dividends Received
=	0	+	-2.694	+	0	+	0
+	Interest Paid	+	Interest Received	+	Taxes Refund Paid	+	Cash Flow from Others
+	0	+	0.377	+	0	+	0
=	-2.32

Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-5.27 Mil.

Invex Therapeutics (ASX:IXC) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Invex Therapeutics's cash receipts from operating activities for the six months ended in Dec. 2023 was A$0.00 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2023 was A$-2.69 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.38 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Invex Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Invex Therapeutics's cash flow from others for the six months ended in Dec. 2023 was A$0.00 Mil.

Invex Therapeutics Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Cash Flow from Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.